Linked Life Data

14559803

Source:http://linkedlifedata.com/resource/pubmed/id/14559803

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
19
pubmed:dateCreated
2003-10-15
pubmed:abstractText
Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-alpha. We examined the expression of cdc25B and phosphorylated ER-alpha in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-alpha was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (chi(2) = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-alpha at high levels, but only 17% (2 of 12) of high-grade EEC did so (chi(2) = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-alpha and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (chi(2) = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-alpha at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (chi(2) = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-alpha and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-alpha occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6195-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:14559803-Adenocarcinoma, Clear Cell, pubmed-meshheading:14559803-Carcinoma, Endometrioid, pubmed-meshheading:14559803-Carcinoma, Papillary, pubmed-meshheading:14559803-Cell Cycle Proteins, pubmed-meshheading:14559803-Cystadenocarcinoma, Papillary, pubmed-meshheading:14559803-Cystadenocarcinoma, Serous, pubmed-meshheading:14559803-Endometrial Neoplasms, pubmed-meshheading:14559803-Estrogen Receptor alpha, pubmed-meshheading:14559803-Female, pubmed-meshheading:14559803-Humans, pubmed-meshheading:14559803-Immunohistochemistry, pubmed-meshheading:14559803-Middle Aged, pubmed-meshheading:14559803-Neoplasm Proteins, pubmed-meshheading:14559803-Phosphorylation, pubmed-meshheading:14559803-Receptors, Estrogen, pubmed-meshheading:14559803-Receptors, Progesterone, pubmed-meshheading:14559803-Uterine Neoplasms, pubmed-meshheading:14559803-cdc25 Phosphatases
pubmed:year
2003
pubmed:articleTitle
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
pubmed:affiliation
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
pubmed:publicationType
Journal Article